Randomized trial · people
PT-141: desire gains over placebo held across RECONNECT subgroups
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In these trials, bremelanotide's edge over placebo for low desire and related distress was broadly consistent across age, body size and testosterone levels.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 1202
- Published
- 2022
- Journal
- J Womens Health (Larchmt)
What they tested
The team tested whether bremelanotide's benefit over placebo for low sexual desire held up across groups split by age, weight, body mass index (BMI) and testosterone level.
How the study was done
A pooled subgroup analysis of two matching randomized, double-blind, placebo-controlled trials in women with hypoactive sexual desire disorder (HSDD, ongoing low sexual desire that causes distress). For 24 weeks, participants injected 1.75 mg bremelanotide or placebo (a dummy shot) under the skin with an autoinjector as needed before sexual activity.

Model. Individual results vary.
What they found
Across 1202 patients, bremelanotide led to significant gains in desire and drops in distress about low desire compared with placebo in every age, weight and BMI subgroup and every testosterone quartile, with few exceptions. In women not using hormonal birth control, the rise in desire was significant (p < 0.05). In those using it, the gain was only numerically higher. Distress fell significantly more than with placebo (p < 0.05) whether or not women used hormonal birth control, and gains held with or without low arousal and no matter how long HSDD had lasted.
What it doesn’t show
This splits two trials into smaller subgroups, and a few subgroups, including desire in hormonal birth control users, did not reach a significant result. It covers the 24-week controlled phase, not the longer open-label extension.
The paper
Simon et al. Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. J Womens Health (Larchmt). 2022.
The compound
More studies on PT-141
- PT-141: side-effect dropouts far higher than placebo in re-analysisMeta-analysis · people · 2021
- PT-141: more responders than placebo at 1.75 mg on all 7 measuresRandomized trial · people · 2019
- PT-141 with alcohol was well tolerated in 24 healthy adultsRandomized trial · people · 2017
- PT-141: +0.7 vs +0.2 satisfying sexual events a month at 12 weeksRandomized trial · people · 2016
- PT-141: nausea in 40.0% vs 1.3% on placebo in phase 3 safety dataSystematic review · people · 2022
- Every study on PT-141
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.